PRLD Share Price Performance
US$4.60
3.77 (455.35%)
54.0% undervalued intrinsic discount
US$10.00
Fair Value
Price US$4.60
AnalystHighTarget US$10.00
AnalystLowTarget US$3.00
Fair ValueUS$10.00
Share Pricen/a
Narrative Update • Jun 26
Prelude Therapeutics Incorporated Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
PRLD Community Narratives
AN
Fair Value
·Fair Value US$10 54.0% undervalued intrinsic discount
Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$3 53.3% overvalued intrinsic discount
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies
Prelude Therapeutics is betting on new cancer drugs that home in on specific disease drivers, with upcoming trial starts that could quickly show whether its science translates in people. The catch is that bigger rivals are already ahead and a key partner can still walk away, so the path forward depends on clean early safety and standout results.Read more
AN
US$10
54.0% undervalued intrinsic discount
Fair Value
Profit Margin
46.21%
Future PE
14.25x
Price in 2029
US$6.85
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?Read more
AN
US$3
53.3% overvalued intrinsic discount
Fair Value
Profit Margin
56.74%
Future PE
3.16x
Price in 2029
US$3.55
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
PRLD: Metastatic Breast Cancer Program Will Drive Upside From Early-Stage Platform
Fair Value: US$10 54.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Fair Value: US$3 53.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Prelude Therapeutics Incorporated Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.78
- 100.00%
- -465.30%
- 0%
About PRLD
- Founded
- 2016
- Employees
- 79
- CEO
- WebsiteView website
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
